secwatch.observer — SEC 8-K summary
======================================

Issuer:     Regen BioPharma Inc (RGBP)
CIK:        0001589150
Form:       8-K
Filed at:   2025-10-03T23:59:59+00:00
Accession:  0001493152-25-016767
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Regen BioPharma issues 40M shares to CEO and consultant for Phase I trial; shares vest on trial success
--------------------------------------------------------------------------------

- Issued 20M shares to CEO David Koos for services in planned Phase I trial of HemaXellerate; shares vest upon trial completion.
- Issued 20M shares to consultant Dr. Harry Lander for same purpose; same vesting condition.
- Total outstanding shares jump to 79,374,704 as of Oct 3, 2025, reflecting ~100% dilution from these grants.
- Phase I trial targets drug-refractory aplastic anemia using autologous stromal vascular fraction from adipose tissue.
- Shares are restricted and unregistered; vest only upon successful trial completion, otherwise forfeited.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1589150/000149315225016767/0001493152-25-016767-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1589150/000149315225016767/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-016767

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer